Inhibition of ADAM10 activity or expression resulted in an increase of trastuzumab efficacy, which suggested that ADAM10 and ADAM17 are tractable targets for HER2-positive trastuzumab-resistant breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.